7/2/2013

Sunovion Pharmaceuticals obtained the FDA's approval to market Latuda, or lurasidone, as a monotherapy and in combination with either lithium or valproate in adults with bipolar depression. The approval was based on favorable data from two double-blind studies.

Related Summaries